Cancer Archives

News and Trends 21 Nov 2016

Celyad’s Autologous CAR-T Therapy enters Phase Ib

Celyad has received approval to start Phase Ib trials in Belgium with its autologous CAR-T therapy, which can target 80% of tumors. After a successful Phase I in leukemia and myeloma, Celyad is ready to start a Phase Ib trial for its autologous NKR-2 in 7 cancer indications, now including solid tumors. The new trial, aimed to examine different […]

November 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 11 17 at 5.37.49 PM e1479400708474

News and Trends 18 Nov 2016

Can Oncolytic Viruses be the key to Treat Resistant Tumors?

This week, we leave Belgium and keep traveling north to Oslo, where snow is starting to pack for the joy of skiers. Meanwhile, Targovax is there working hard to treat cancer with its immunotherapy pipeline. City: Oslo, Norway Founded: 2010 Employees: 20 – 30 Financial data: €12M raised in a private placement in July Mission: Targovax develops immuno-oncology […]

November 18, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 17 Nov 2016

Boehringer’s Biosimilar could take a Chunk out of the Cancer Market

Boehringer Ingelheim is getting ready to launch a biosimilar for Roche’s cancer blockbuster Avastin as soon as the patent expires. Can it overcome the fierce competition in a market expected to grow to 50% of the drug market by 2020? Boehringer Ingelheim just announced results from a Phase I trial showing that its biosimilar candidate […]

November 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Nov 2016

New Private Placement to Boost the Profitable Therapeutic Antibody Market

MorphoSys has announced a private placement of shares to raise funds for its antibody therapy programs. With this push, the company is solidifying its position as a leader in the therapeutic antibody market, which is expected to reach €117B by 2021. MorphoSys, one of the few European billion euro biotechs, develops therapeutic antibodies for immuno-oncology, inflammatory […]

November 16, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Nov 2016

Microbiomics recruited for Immuno-Oncology in a Huge New Partnership

What if the bacteria in your gut could help fight cancer? Enterome is partnering with Bristol-Myers Squibb to explore this possibility and develop microbiome-related therapeutics and diagnostics for immuno-oncology. Enterome, one of the coolest biotechs in Paris, specializes in the isolation of bacteria and microbial targets linked to immune modulation and inflammation. With an impressive […]

November 16, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Nov 2016

Cell Therapies: Is Commercialization holding back a Breakthrough?

How far away is biotech from a breakthrough with cell and gene therapy? While these therapies have the potential to be the most effective on the market, they are still a long way away from that point, according to a pair of expert panels at BIO Europe last week. Everyone in cell therapy knows the […]

November 16, 2016 - 4 minutesmins - By Evelyn Warner

News and Trends 15 Nov 2016

Red Blood Cells as Cancer Drug Carriers: Market Approval gets Delayed

Erytech will have to provide additional data before re-applying for market approval in Europe for Graspa. This leukemia therapy uses red blood cells to deliver an enzyme that starves tumors to death. Erytech is a biotech from Lyon with a visionary approach to treat cancer: using red blood cells as drug carriers. Last year, the company […]

November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Nov 2016

How much of a Gamble is Investing in CRISPR?

CRISPR is going to change a lot in the life science industry and is perceived as THE discovery of the 21st century. Within the past 6 months, 3 companies went public, raising between €50M and €100M each (with valuation close to the billion), to bring about the CRISPR revolution. But the problem is, there is absolutely […]

November 15, 2016 - 4 minutesmins - By Philip Hemme

News and Trends 10 Nov 2016

UPDATE: FDA Lifts Hold on Adaptimmune’s Rare Cancer Trials

The FDA puts one of Adaptimmune‘s TCR trials on a partial hold, pending more information about the production of its cell therapy. It’s more waves for the Biotech’s financial rocking boat. Oxford-based Adaptimmune is one of the European players in TCR therapies. Besides being listed on the NASDAQ, it got GSK on board on a €311M […]

November 10, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 10 Nov 2016

European Biotech is working hard to Beat back Melanoma

Immunocore and Pierre Fabre have been representing Europe in this years’ Society for Melanoma Research Congress. This type of cancer may have its days counted! This week, scientists from around the globe met at the MRC to get an update on what’s going on in the fights against melanoma, the least common but most deadly skin […]

November 10, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 9 Nov 2016

Up, up and away! CureVac’s money pile now Totals €325M

CureVac has raised an additional €27M ($29.5M) that will help the company keep on its track to be the first one to launch a mRNA therapy, a technology that can revolutionize how drugs are designed. CureVac is a German company in the billion-euro biotech club at the forefront of messenger RNA (mRNA) therapies, a technology that […]

November 9, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Nov 2016

Catching Up with the French Leader in Immuno-Oncology #BIOEurope

Despite the deflating attitudes towards immuno-oncology, OSE Immunotherapeutics is forging ahead. We caught up with the CEO, Dominique Costantini, at BIO Europe to make our first video Interview. OSE Immunotherapeutics is developing immunotherapy products against invasive and metastatic late-stage cancers. Memopi is one of its key technologies, and it is currently under development for ovarian, colon and breast […]

November 7, 2016 - 1 minutemin - By Philip Hemme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

Celyad’s Autologous CAR-T Therapy enters Phase Ib

Can Oncolytic Viruses be the key to Treat Resistant Tumors?

Boehringer’s Biosimilar could take a Chunk out of the Cancer Market

New Private Placement to Boost the Profitable Therapeutic Antibody Market

Microbiomics recruited for Immuno-Oncology in a Huge New Partnership

Cell Therapies: Is Commercialization holding back a Breakthrough?

Red Blood Cells as Cancer Drug Carriers: Market Approval gets Delayed

How much of a Gamble is Investing in CRISPR?

UPDATE: FDA Lifts Hold on Adaptimmune’s Rare Cancer Trials

European Biotech is working hard to Beat back Melanoma

Up, up and away! CureVac’s money pile now Totals €325M

Catching Up with the French Leader in Immuno-Oncology #BIOEurope

Subscribe to our newsletter to get the latest biotech news!